pros and cons of glp-1 drugs 2026 Employee Benefits Trends: Should You Cover GLP‑1s for Weight Loss? GLP-1 receptor agonists, sometimes called

GLP-1 weight loss drugs are reshaping US food consumption, reducing snack intake and driving industry shifts in nutrition, labels and product innovation.

GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure

These diet

A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D

This Comment highlights emerging evidence and advocates for clinical strategies that prioritize muscle preservation to ensure the long-term success and safety of pharmacological weight management.